摘要
Abstract
Objective To investigate the efficacy and safety of programmed death protein-1(PD-1)inhibitors combined with antiangiogenic agents in the treatment of advanced non-small cell lung cancer(NSCLC).Methods From January 2019 to November 2021,total 137 patients with advanced NSCLC admitted to our hospital were selected as study objects and divided into two groups according to treatment methods.There were 81 patients treated with PD-1 inhibitor combined with antiangiogenic drugs(combination group),and 56 patients treated with PD-1 inhibitor monotherapy(monotherapy group).Objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS),vascular endothelial growth factor(VEGF),tumor volume(TV),prognostic survival curve and related data of toxic and side effects were statistically analyzed.Results ORR and DCR in combination group were significantly higher than those in monotherapy group with statistically signifi-cant difference(x2=4.219,3.583;P=0.040,0.045).PFS and OS in combination group were significantly longer than those in monotherapy group with statistically significant difference(Z=7.017,5.778;P<0.001).VEGF and TV in both groups decreased significantly after experiment(P<0.001),and VEGF and TV in combination group were significantly lower than those in mono-therapy group after experiment 1 and 2 cycles,with statistical significance(P<0.001).Kaplan-Meier prognosis and survival curves between two groups showed statistically significant difference(x2L=5.338,P=0.027).The incidence of nausea,vomiting,headache,fatigue,diarrhea,rash,anemia,constipation,dyspnea and arthralgia and the incidence of side effects above gradeⅢwere not statistically significant between two groups(P>0.05).Conclusion PD-1 inhibitors combined with antiangiogenic drugs could inhibit tumor microvascular hyperplasia,reduce TV,increase ORR and DCR,prolong PFS and OS.The incidence of side effects above grade Ⅲ is low,and the side effects are generally safe and controllable,which helps to increase the benefit of patients with advanced NSCLC.关键词
非小细胞肺癌/晚期/程序性死亡蛋白-1/抗血管生成药物/安全性/疗效Key words
non-small cell lung cancer/advanced/programmed death protein-1/antiangiogenic drugs/safety/curative effect分类
医药卫生
